Aerie (AERI) September volatility at 190 into 'successful' efficacy results of Phase 3 Roclatan trial
Get Alerts AERI Hot Sheet
Join SI Premium – FREE
Aerie Pharma (NASDAQ: AERI) is recently up $12.17 to $33.30 in the premarket after reporting 'successful' efficacy results of Phase 3 Roclatan trial. September call option implied volatility is at 190, October is at 200; compared to its 52-week range of 63 to 274.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Charter Communications (CHTR) option IV flat as share price near low end of range
- Qualcomm (QCOM) call put ratio 3.5 calls to 1 put with a focus on March weekly (22) calls
- SoundHound AI (SOUN) option implied volatility amid wide price movement
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!